New Delhi: The Subject Expert Committee (SEC) functioning under the Central Drugs Standard Control Organisation (CDSCO) has granted approval to Zenvision Pharma LLP to conduct a bioequivalence (BE) study for its proposed Rifaximin sachets of 400 mg and 550 mg strength.

This came after the firm presented the proposal for a grant of permission to manufacture and market Rifaximin sachets of 400 mg and 550 mg along with Bioequivalence study protocol.

Rifaximin is a rifamycin-based non-systemic antibiotic used for the treatment of gastrointestinal bacterial infections, such as traveler's diarrhea and irritable bowel syndrome, and reduction of overt hepatic encephalopathy recurrence in adults.

Rifaximin acts by inhibiting RNA synthesis in susceptible bacteria by binding to the beta-subunit o

See Full Page